Lupin Launches Diabetes Drug In US Market After FDA Approval; Shares Fall 0.58%

Mumbai, April 22: Lupin Limited has introduced its Dapagliflozin and Metformin Hydrochloride extended-release tablets in the United States after securing approval from the US Food and Drug Administration.

The therapy has been launched in four dosage combinations, designed to support glycaemic control in adults with type 2 diabetes. The approval was granted under the abbreviated new drug application pathway, with the product positioned as a bioequivalent version of Xigduo XR, the company said in an exchange disclosure.

This launch adds another layer to Lupin’s US generics playbook.

Stock Market Snapshot

Lupin share price was quoted at ₹2,298.00, lower by 0.58% as of 10:02 IST on April 22, 2026, compared with its previous close of ₹2,311.50, as per exchange data.

The session opened at ₹2,304.70 and saw the stock move between ₹2,285.10 and ₹2,313.70 in the morning trade. The reaction, while negative, remained contained.

Such muted movement is not uncommon. Investors often look beyond the announcement itself, focusing instead on how quickly the product scales up, the level of competition in the US market, and pricing pressure in the segment.

Established Presence Across Global Pharma Markets

Lupin Limited operates across more than 100 markets, with a portfolio spanning generics, branded formulations, biotechnology products, and active pharmaceutical ingredients.

Its operations are backed by 15 manufacturing facilities and 7 research centres worldwide. The company has built a steady presence in key therapeutic areas including diabetes, cardiovascular diseases, respiratory conditions, and anti-infectives.

The US remains a critical geography. Over the years, Lupin has focused on expanding its pipeline in complex generics and specialty segments, where regulatory approvals often translate into differentiated opportunities.

Expansion Strategy Hinges On Execution In US Market

The latest product launch reinforces Lupin’s ongoing push to deepen its footprint in regulated markets, particularly the United States.

According to the company’s filing, the approval strengthens its diabetes portfolio, but the commercial trajectory will depend on prescription uptake and competitive positioning. Pricing discipline and distribution reach will also play a role.

Source:

• https://www.nseindia.com/get-quote/equity/LUPIN/Lupin-Limited
• https://nsearchives.nseindia.com/corporate/Lupin2_22042026091137_SELetterPressRelease.pdf